2026-08-27
$70M of new funding is targeting patient access and care coordination
1 funded company building into patient access and care coordination. The work in scope is what the Director of Patient Access owns today.
The funding
EXUMA Biotech is a clinical-stage biotech company advancing gene vector delivery to enhance patient access to innovative cell and gene therapies.
EXUMA Biotech Corp. Form D filing →What it means
Capital arriving in a function is a reliable leading indicator. It does not mean the incumbents are wrong, and it does not mean these companies will succeed. It means that within the next few quarters the people who run this work will be asked what their function is doing about it, and the honest answer has to start with where that function actually stands.
So we built the assessment for it. Not a purchase decision, a structured set of questions to take to your own team.